Cipla Shares Slide 2% Following Q1 FY27 Results: Net Profit Drops 39% to ₹789 Crore Amid North American Headwinds

Cipla Limited reported a 39.2% fall in Q1 FY27 net profit to ₹789 crore, missing analyst expectations.

The profit decline was driven by price erosion in generic cancer therapies including Revlimid and supply disruptions for lanreotide.

Cipla's stock fell over 2% to around ₹1,386 after opening at ₹1,409.10.

The US FDA classified the Goa facility inspection as Voluntary Action Indicated (VAI) in June 2026, clearing a regulatory hurdle.

Shivam Puri was appointed CEO of Cipla's 'One India' business effective July 1, 2026, to accelerate growth in consumer health and chronic therapies.